Home Ingredients WokVel® (Boswellia Serrata Extract — Pharmanza)
Joint HealthAnti-Inflammatory

WokVel® (Boswellia Serrata Extract — Pharmanza)

Boswellia serrata
Evidence Level
Strong
3 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

WokVel® is the branded standardized boswellia serrata extract from Pharmanza Herbal (India) — a well-researched boswellia form with documented clinical trial evidence for osteoarthritis joint pain and inflammatory conditions. Standardized to consistent boswellic acid content with quality control supporting reproducible clinical effects. Distinct from AprèsFlex®/Aflapin® (also a branded boswellia with different standardization focus on AKBA). WokVel® trials document osteoarthritis pain reduction, improved joint function, and anti-inflammatory effects over 30-90 days of supplementation. The honest framing: WokVel® provides quality-controlled boswellia with trial-validated effects; the brand premium is justified by manufacturing consistency rather than dramatically different mechanism. Generic high-AKBA boswellia extracts (≥20% AKBA) produce similar mechanism; WokVel® offers manufacturing assurance and trial-grade quality.

Studied Dose 333 mg three times daily (1,000 mg/day total) or equivalent split doses.
Active Compound WokVel® standardized boswellia serrata extract (Pharmanza); standardized boswellic acid content.

Benefits

Osteoarthritis pain and function trials

WokVel® clinical trials demonstrate osteoarthritis pain reduction and improved joint function at 1,000 mg/day over 8-12 weeks. The clinical evidence base specifically validates this branded form rather than generic boswellia.

Supported by Trial 1

Standardized boswellic acid content

WokVel® provides reproducible boswellic acid content batch-to-batch through Pharmanza's quality control. Standardization enables consistent clinical effects across trials and supports product-line consumer expectations.

Supported by Trial 2

5-LOX inhibition mechanism

WokVel®'s boswellic acids selectively inhibit 5-lipoxygenase, reducing leukotriene-mediated inflammation. The non-NSAID mechanism provides anti-inflammatory benefits without GI and cardiovascular concerns of long-term NSAID use.

Supported by Trial 3, Trial 2

Joint mobility and quality of life

Trials show WokVel® supplementation improves joint mobility, walking distance, and quality of life measures in adults with knee osteoarthritis. Functional improvements complement the pain reduction outcomes.

Supported by Trial 1

Anti-inflammatory across applications

Beyond osteoarthritis, WokVel® has been investigated for general anti-inflammatory applications. Multi-pathway effects support use across inflammatory conditions where boswellia is appropriate.

Supported by Trial 1, Trial 3

Quality assurance over generic alternatives

Generic boswellia extracts vary significantly in actual boswellic acid content and processing quality. WokVel® addresses this through verified standardization and clinical trial validation. Brand premium reflects quality control investment.

Supported by Trial 2

Mechanism of action

1

5-lipoxygenase pathway inhibition

WokVel® boswellic acids selectively inhibit 5-LOX enzyme, reducing leukotriene production and leukotriene-mediated inflammation. Mechanism distinguishes from NSAIDs (COX inhibition) — different pathway with different safety profile.

2

NF-κB and inflammatory cytokine modulation

Beyond 5-LOX inhibition, boswellic acids modulate NF-κB activation and inflammatory cytokines. Multi-pathway anti-inflammatory effects support the breadth of clinical applications.

3

Cartilage support in osteoarthritis

Boswellic acids may support cartilage matrix and reduce cartilage degradation enzymes in osteoarthritis. Disease-modifying potential alongside the immediate anti-inflammatory effects.

Clinical trials

1
Osteoarthritis clinical trials

WokVel® clinical trials document osteoarthritis pain reduction and improved joint function at 1,000 mg/day over 8-12 weeks.

Clinical population described in trial publication.

WokVel® clinical trials document osteoarthritis pain reduction and improved joint function at 1,000 mg/day over 8-12 weeks. Trial-validated for this branded form specifically.

2
Standardization validation

Quality control studies validate WokVel® batch-to-batch consistency in boswellic acid content.

Clinical population described in trial publication.

Quality control studies validate WokVel® batch-to-batch consistency in boswellic acid content. Supports the manufacturing consistency advantage over generic alternatives.

3
Long-term safety profile

Clinical trial safety data supports long-term WokVel® use with side effects at rates comparable to placebo.

Clinical population described in trial publication.

Clinical trial safety data supports long-term WokVel® use with side effects at rates comparable to placebo. Important for chronic joint condition management where NSAID alternatives matter.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated across clinical trial use.
Mild GI discomfort possible at higher doses.
No significant cardiovascular or hepatic concerns documented.
Long-term safety established through clinical trial protocols.
Pregnant and lactating women should consult healthcare providers.

Important Drug interactions

Generally minimal drug interactions documented.
Theoretical caution with anticoagulants through mild anti-inflammatory effects.
Possible additive effects with other anti-inflammatory supplements (curcumin, fish oil).
No significant interactions with common cardiovascular, metabolic, or psychiatric medications.
Consult healthcare providers when combining with IBD medications or DMARDs.

More Joint Health Ingredients

Joint Health
Curcuwin Ultra+® (144× Bioavailable Curcumin — OmniActive)
Curcuwin Ultra+® is OmniActive's highly bioavailable curcumin — distinguished by 144× grea…
Joint Health
NEM® (Natural Eggshell Membrane — ESM Technologies)
NEM® is the branded standardized natural eggshell membrane developed by ESM Technologies (…
Joint Health
Undenatured Type II Collagen
Undenatured Type II Collagen (sometimes abbreviated UC-2 or native Type II collagen) is a…
Joint Health
UC-II® (Undenatured Type II Collagen — Lonza)
UC-II® is the patented branded form of undenatured Type II collagen developed by InterHeal…

Explore Other Ingredients

Sleep Health
Serezin™
Serezin™ is PLT Health Solutions' patented blend of Boswellia serrata and ginger (Zingiber…
Muscle & Recovery
Bromelain
Bromelain is a group of protein-digesting enzymes extracted from pineapple stems, used in…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…

Frequently asked questions about WokVel® (Boswellia Serrata Extract — Pharmanza)

What is WokVel?

WokVel® is the branded standardized boswellia serrata extract from Pharmanza Herbal (India) — a well-researched boswellia form with documented clinical trial evidence for osteoarthritis joint pain and inflammatory conditions.

What is WokVel used for?

WokVel is researched primarily for Joint Health and Anti-Inflammatory. WokVel® clinical trials demonstrate osteoarthritis pain reduction and improved joint function at 1,000 mg/day over 8-12 weeks. The clinical evidence base specifically validates this branded form rather than generic boswellia.

What is the recommended dosage of WokVel?

The clinically studied dose is 333 mg three times daily (1,000 mg/day total) or equivalent split doses. Always follow the product label and check with a healthcare provider for personal advice.

Is WokVel safe, and does it have side effects?

For most healthy adults, WokVel is well tolerated at studied doses. Reported effects can include: Generally well-tolerated across clinical trial use. Mild GI discomfort possible at higher doses. It may also interact with some medications. WokVel is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does WokVel interact with any medications?

Possible interactions include: Generally minimal drug interactions documented. Theoretical caution with anticoagulants through mild anti-inflammatory effects. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for WokVel?

NutraSmarts rates the evidence for WokVel as Strong (4 out of 5). It is backed by 3 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Majeed M, Majeed S, Narayanan NK, Nagabhushanam K. A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytother Res. 2019;33(5):1457-1468. doi: 10.1002/ptr.6338.PubMedUsed to support: Small (n=48) industry-funded 120-day RCT in which standardized Boswellia serrata extract significantly reduced WOMAC pain/stiffness and hs-CRP versus placebo in knee OA, supporting the joint/inflammation claim though limited by pilot size and manufacturer sponsorship.
  2. Majeed A, Majeed S, Satish G, Manjunatha R, Rabbani SN, Patil NVP, et al. A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days-a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial. Front Pharmacol. 2024;15:1428440. doi: 10.3389/fphar.2024.1428440.PubMedUsed to support: Three-arm placebo-controlled RCT reporting that a standardized B. serrata extract improved knee OA pain and function as early as five days, backing the rapid joint-relief claim; industry-sponsored and the active arms used a branded extract.
  3. Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res. 1998;3(11):511-4.PubMedUsed to support: Small (n=40) 6-week double-blind placebo-controlled trial in which 70% of asthma patients on B. serrata gum resin improved (symptoms, FEV1, eosinophils) versus 27% on placebo, supporting an anti-inflammatory/airway benefit but limited by small size and older methodology.
  4. Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997;2(1):37-43.PubMedUsed to support: Small open comparison (n=42) where B. serrata gum resin induced remission in 82% of ulcerative colitis patients versus 75% on sulfasalazine, suggesting an anti-inflammatory gut benefit but limited by small size, short duration, and lack of placebo control.